Cetuximab-IRDye 800CW in Detecting Tumors in Patients With Malignant Glioma Undergoing Surgery
Status:
Terminated
Trial end date:
2016-11-22
Target enrollment:
Participant gender:
Summary
This study is a phase 1-2 trial that evaluates the best dose of cetuximab-IRDye 800CW and how
well it works in detecting tumors in patients with malignant glioma who are undergoing
surgery. Cetuximab-IRDye 800CW is an optical imaging agent that may help detect tumor cells
when a special camera is used.